Drugs / Epstein-Barr Virus Specific T-Lymphocytes
Epstein-Barr Virus Specific T-Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06909110 | Apr 2025 → May 2029 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epstein-Barr Virus Specific T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06909110 ↗ |
| Modality | Cell therapy | “viral specific T cells generated by gamma capture technology” NCT06909110 ↗ |